NCT06974097Not yet recruiting
Tumor Associated Neutrophils as a Biomarker of Chemo-immunotherapy Response in Locally Advanced Non-small Cell Lung Cancer : a Model Based on Neoadjuvant Strategy
Source: ClinicalTrials.gov · Last updated 8 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
evaluate the predictive value of circulating neutrophil DNA methylation profiles, identified from the ALCINA 2 cohort, on pre-treatment blood samples (T0), for the histological response to neoadjuvant chemo-immunotherapy in patients with resectable non-small cell lung cancer (NSCLC)
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 72 (estimated)
- First submitted
- 7 May 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 28 Jul 2028
- Lead sponsor
- University Hospital, Montpellier
- Diseases
- Lung cancer
- NCT number
- NCT06974097
What you commit to
- Study type: Observational
- Planned participants: 72
- From 1 Jul 2025 to the primary completion date, 28 Jul 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous systemic treatment for the same CBNPC.
- Contraindication to immunotherapy.
Other
- Diagnosis of another solid tumor within the last 3 years, ‡ excluding non melanoma cutaneous and cervical carcinomas .
- Non-objection to participate in research not collected.
- Patients unable to read and/or write.
- Inability to monitor patient during study period
- Persons unable to express their consent.
- Not affiliated to a social security scheme.
- Persons under court protection.
- Persons participating in another research study with an ongoing exclusion period.
- Pregnant women
Who the study is looking for
- Age ≥ 18 years.
- Resectable non-small cell lung cancer (NSCLC), stage IIA to IIIB.
- Lymph node status obtained by Positron Emission Tomoscintigraphy (PET)-scanner, confirmation of lymph node status by optional histological sampling (mediastinoscopy, thoracoscopy, echo-endoscopy).
- No secondary lesions in the cerebrum or extra-cerebrum confirmed on brain MRI, PET scanner +/- injected cerebro-thoraco-abdomino-pelvic scanner.
- Neoadjuvant immunochemotherapy strategy validated by a multidisciplinary consultation meeting (RCP) prior to the start of treatment.
- Lung function compatible with thoracic surgery, patient meets surgical and anesthetic criteria for operability
- Measurable disease according to RECIST criteria version 1.1
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de Montpellier - Hôpital Arnaud de Villeneuve Coordinator of this site? Confirm its status | Montpellier | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.